Reckitt Bids Up Bayer For Schiff Nutrition
This article was originally published in The Tan Sheet
Reckitt says its $42 per-share cash offer values Schiff at around $1.4 billion, 23/.5% more than Bayer’s $1.2 billion bid, roughly $34 per share, for the Salt Lake City-based firm.
You may also be interested in...
Kind’s Specific Ingredient Claims Remain Airborne After General Comparison To Clif Bar Line Grounded
National Advertising Division says a TV commercial Kind previously aired claiming “75% less sugar than the leading Clif bar” made an unfair “line claim.” But Kind says "ultimately this issue is moot" as it stopped using the "commercial (which takes place on an airplane) many months ago in light of the COVID-19 pandemic.”
“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.